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1. Disease characteristics 
1.1 Name of the Disease (Synonyms): 
Aniridia (Aniridia II) 
 
1.2 OMIM# of the Disease:  
106210 
 
1.3 Name of the Analysed Genes or DNA/Chromosome Segments: 
PAX6, ELP4. 
 
1.4 OMIM# of the Gene(s): 
607108 (PAX6), 606985 (ELP4). 
 
1.5 Mutational Spectrum: 
 
Approximately two-thirds of aniridia cases are familial with autosomal dominant inheritance, 
the remainder are sporadic.1 Aniridia occurs either as an isolated ocular abnormality or as 
part of the Wilms tumour-aniridia-genital anomalies-retardation (WAGR) syndrome (see 
Clinical Utility Gene Card for WAGR syndrome).2 Loss of function of one copy of the PAX6 
gene (NCBI reference sequence NM_001310160.1, NM_001310161.1) occurs in around 
90% of aniridia cases, with intragenic variants accounting for two-thirds and chromosomal 
rearrangements for one-third of patients. Over 94% of all intragenic point variants result in 
either premature termination codons (mainly through nonsense, splice and frame-shift 
insertions or deletions), C-terminal extensions (CTE) or missense changes.1 To date 
(January 2016), 403 unique PAX6 gene variants have been submitted to the online Human 
PAX6 Mutation Database (http://pax6/hgu.mrc.ac.uk/). These variants are scattered 
throughout the PAX6 gene, generally disrupting transcription or translation. To date, of the 
696 public entries in the PAX6 Mutation Database, over 100 different premature termination 
codons are recorded, with approximately 20% accounted for by just four common nonsense 
variants of arginine (R) residues: c.607C>T, p.R203* (36 reports); c.718C>T, p.R240* (48 
reports); c.781C>T, p.R261* (19 reports); and c.949C>T, p.R317* (35 reports). The CTE 
variants are associated with more severe aniridic phenotypes,3,4 the c.1267dupT has been 
reported 21 times.  
 
One case of aniridia was reported to have been caused by a heterozygous point variant in 
the ultra-conserved PAX6 cis-regulatory element (SIMO) that resides 150 kb downstream 
from PAX6 in intron 9 of the ELP4 gene (NCBI reference sequence NM_001288726.1).5 
Deletion of regulatory elements, or their separation from the PAX6 transcription machinery 
through inversion or translocation breakpoints, may manifest with a classical aniridic 
phenotype. There have been a few reports on aniridia-like phenotypes secondary to variants 
in FOXC1.6,7  
 
1.6 Analytical Methods: 
Array comparative genomic hybridisation (CGH) or multiplex ligation-dependent probe 
amplification assay (MLPA) should be performed initially to detect deletions or duplications, 
then bi-directional fluorescent Sanger sequencing of coding and intron–exon boundaries of 
PAX6 should follow. Some molecular service labs offer fluorescence in situ hybridisation 
(FISH) to identify rearrangements that may disrupt PAX6 without copy number change.8,9 
 
1.7 Analytical Validation 
Parallel bi-directional fluorescent Sanger sequencing of known controls is required to validate 
procedures. Diagnostic testing must be carried out within a laboratory environment working 
to standards compliant with the ISO 15189.  
 
1.8 Estimated Frequency of the Disease  
(Incidence at birth ("birth prevalence") or population prevalence. If known to be variable 
between ethnic groups, please report): 
The prevalence of aniridia in the general population is between 1 in 40,000-100,000 with no 
known predilection for a particular race or gender.  
 
1.9 Diagnostic Setting: 
 Yes. No. 
A. (Differential) diagnostics    
B. Predictive Testing    
C. Risk assessment in Relatives    
D. Prenatal    
 
Comment: Not applicable
2. Test characteristics 
 
 
2.1 Analytical Sensitivity 
(proportion of positive tests if the genotype is present) 
The analytical sensitivity and specificity of bi-directional Sanger sequencing is estimated to 
be >98% for the detection of nucleotide base changes, small deletions and insertions in the 
regions analysed. Analytical sensitivity and specificity of MLPA testing is essentially 100% 
with appropriate testing; very rarely sub-microscopic deletions may reduce analytical 
sensitivity of MLPA. Patients who appear not to have variants on testing described above, 
may have deep intronic or other variants in the regulatory elements missed through exonic 
analysis. 
 
2.2 Analytical Specificity 
(proportion of negative tests if the genotype is not present) 
See above. Estimated analytical specificity of >98% given current testing methodologies, 
based on false positives that may arise due to misinterpretation of rare polymorphic variants 
that rarely occur in Sanger sequencing.  
 
2.3 Clinical Sensitivity 
(proportion of positive tests if the disease is present) 
The clinical sensitivity can be dependent on variable factors such as age or family history. In 
such cases a general statement should be given, even if a quantification can only be made 
case by case. 
 
Aniridia presents in infancy, typically characterised by complete or partial iris hypoplasia and 
foveal hypoplasia, resulting in reduced visual acuity and nystagmus. There are progressive 
features including cataract, glaucoma and corneal abnormalities. The clinical sensitivity is 
>98%. Although rare phenocopies do exist and include dominant alleles of FOXC1, PITX2 
and PITX3 which can cause diagnostic difficulties. 6,7,10,11 Phenotypically subtle PAX6 
variants have been documented 12-14, including those that segregate with nystagmus, foveal 
hypoplasia and autosomal dominant keratitis in the absence of iris abnormalities supporting 
the concept of dosage effects the gene, variable expressivity and gonadal mosaicism.15 
Deep phenotyping studies have revealed smaller corpus callosum area on brain volumetry 
following magnetic resonance imaging, and subtle hearing difficulties associated with 
interhemispheric transfer problems.16 The clinical examination alone in atypical phenotypes 
would not lead to a PAX6-related molecular diagnosis, highlighting the importance of genetic 
testing. 
 
2.4 Clinical Specificity 
(proportion of negative tests if the disease is not present) 
The clinical specificity can be dependent on variable factors such as age or family history. In 
such cases a general statement should be given, even if a quantification can only be made 
case by case. 
Aniridia is a congenital disorder, a positive test in a patient without signs of this condition is 
unlikely, and hence the clinical specificity will be high, nearing 100%.  
 
2.5 Positive clinical predictive value 
(life time risk to develop the disease if the test is positive) 
Estimated >99% for PAX6 variants, as aniridia presents in infancy with high penetrance. 
 
2.6 Negative clinical predictive value 
(Probability not to develop the disease if the test is negative). 
Assume an increased risk based on family history for a non-affected person. Allelic and locus 
heterogeneity may need to be considered.  
Index case in that family had been tested: 
Nearly 100% if no aniridia. 
 
Index case in that family had not been tested: 
Nearly 100% if no aniridia, however the clinical phenotype can be variable with subtle signs 
and familial recurrence if parental mosaicism, partial or non-penetrance exists, therefore it is 
recommended that the family is tested.17 
3. Clinical Utility 
3.1 (Differential) diagnostics: The tested person is clinically affected 
       (To be answered if in 1.9 "A" was marked) 
 
3.1.1 Can a diagnosis be made other than through a genetic test? 
 
No.  (continue with 3.1.4) 
Yes,  
 clinically.   
imaging .  
 endoscopy.   
 biochemistry.   
 electrophysiology.  
other (please describe): 
 
 
 
3.1.2 Describe the burden of alternative diagnostic methods to the patient 
Patients with suspected aniridia can be diagnosed based on clinical examination, 
predominantly with the slit-lamp (hand-held for infants) to identify iris and pupillary 
abnormalities, corneal opacification and vascularisation, and cataract or glaucoma. 
Fundoscopy (indirect ophthalmoscopy for infants) may reveal foveal hypoplasia and 
associated optic nerve abnormalities, however, an examination under anaesthesia may be 
required. Optical coherence tomography (OCT) may be useful to document foveal 
hypoplasia, but this may be difficult in the presence of nystagmus and in young children, 
though hand-held OCT may help.18 If severe corneal opacity or oedema exists due to 
congenital glaucoma, anterior segment ultrasound biomicroscopy may aid detection of any 
iris defects.  
 
3.1.3 How is the cost effectiveness of alternative diagnostic methods to be judged?  
Aniridia is a rare disorder, and patients will often require tertiary referral for accurate 
diagnosis. Clinical examination provides a cost-effective diagnosis, but high-resolution 
imaging can be costly. 
 
3.1.4 Will disease management be influenced by the result of a genetic test? 
No.  
 
Yes.  
Therapy (please describe)  Pharmacological approaches such as translational 
bypass therapy using ataluren are being developed to 
treat nonsense-mediated aniridia.19  
 
Prognosis (please describe)  The genotype has been associated with disease 
severity; null variants predominantly cause classical 
aniridia with iris aplasia and progressive sight-
threatening disease.3 CTE variants are associated with 
more severe aniridic phenotypes,4 whereas missense 
variants produce a variable spectrum ranging from mild 
iris defects and preserved visual acuity to severe 
features including optic nerve malformations, Peters 
anomaly and microphthalmia.20,21 
 
 Management (please describe) Aniridia should be managed by specialists with 
expertise in this condition. Supportive measures for 
those with sight impairment include involvement of 
social services. Regular follow-up will be required to 
monitor progression of corneal disease, cataract and 
glaucoma with medical and surgical interventions where 
needed. Regular refraction and provision of tinted or 
photochromic lenses to reduce light sensitivity. Genetic 
counselling will be offered to the family. Audiological 
evaluation may help identify and support early school 
age children with aniridia-associated central auditory 
processing deficits.(15) 
 
 
 
3.2 Predictive Setting: The tested person is clinically unaffected but carries an 
increased risk based on family history 
     (To be answered if in 1.9 "B" was marked) 
 
3.2.1 Will the result of a genetic test influence lifestyle and prevention? 
If the test result is positive (please describe) 
The result may impact on career choices and inform family planning. Currently, no medical or 
lifestyle therapies exist to prevent sight deterioration or disease progression. If a deletion 
involves both PAX6 and WT1 leading to a risk of Wilms tumour the influence on lifestyle will 
significantly change, please refer to the management section of the Clinical Utility Gene Card 
for WAGR syndrome.2 
 
If the test result is negative (please describe) 
The result will inform family planning.  
 
3.2.2 Which options in view of lifestyle and prevention does a person at-risk have if no 
genetic test has been done (please describe)? 
Some aniridic patients may be ‘legally blind’ or experience progressive vision loss making 
professions that require perfect vision near impossible. Hence, a clinically confirmed 
diagnosis can help to provide guidance in career choice.  
 
3.3 Genetic risk assessment in family members of a diseased person 
     (To be answered if in 1.9 "C" was marked) 
3.3.1 Does the result of a genetic test resolve the genetic situation in that family? 
Yes. 
 
3.3.2 Can a genetic test in the index patient save genetic or other tests in family 
members? 
No. Parents of an index patient with a de novo gene variant should be examined for subtle 
aniridic changes, and be checked for parental mosaicism or non-penetrance.  
 
3.3.3 Does a positive genetic test result in the index patient enable a predictive test in 
a family member? 
Yes. Seventy percent of patients with isolated aniridia have an affected parent.22 Risk to 
siblings is dependent on the genetic status of the proband’s parents.23 
 
3.4 Prenatal diagnosis 
     (To be answered if in 1.9 "D" was marked) 
Prenatal diagnosis is offered to patients with a confirmed disease-causing PAX6 variant or 
regulatory region deletion to enable them to be fully informed, however, acting upon the 
result in terms of termination is not normally advised as this condition can have a variable 
clinical phenotype. An individual with isolated aniridia has a 50% chance of passing the 
PAX6 pathogenic variant to their offspring. If the parents appear unaffected but they have an 
affected child, rare germ line mosaicism can exist, this should be investigated in order to 
identify the risk to further siblings.  
 
3.4.1 Does a positive genetic test result in the index patient enable a prenatal 
diagnosis? 
Yes. Prenatal testing using fetal cells obtained by amniocentesis (~15 to 18 weeks gestation) 
or chorionic villus sampling (~10 to 12 weeks gestation) is possible for pregnancies at 
increased risk for isolated aniridia if the pathogenic variant or regulatory region deletion has 
been identified.24 
 
 
4. If applicable, further consequences of testing 
Please assume that the result of a genetic test has no immediate medical consequences. Is 
there any evidence that a genetic test is nevertheless useful for the patient or his/her 
relatives? (Please describe) 
Yes. Understanding the genetic result provides information regarding recurrence risk, 
inheritance patterns, facilitates decision making through effective genetic counselling, 
enables patients to participate in research studies including clinical trials and join 
organisations such as the Aniridia Foundation International (AFI) for support and guidance.  
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